Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Short Communications

Cimetidine Use and Risk of Prostate and Breast Cancer

Mary Anne Rossing, Delia Scholes, Kara L. Cushing-Haugen and Lynda F. Voigt
Mary Anne Rossing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Delia Scholes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kara L. Cushing-Haugen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynda F. Voigt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published March 2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    Risk of breast cancer among female users of H2 blockers in GHC relative to the general population of western Washington State, 1977–1996

    ObservedExpectedSIR95% CI
    All users507518.21.00.9–1.1
    Time since cohort entry (mo)
      0–116876.80.90.7–1.1
     12–59223234.81.00.8–1.1
     60–119154149.81.00.9–1.2
    120+6256.81.10.8–1.4
    By type(s) of H2 blocker used
    Cimetidine only267281.80.90.8–1.1
    Time since cohort entry (mo)
      0–113042.00.70.5–1.0
     12–59118122.51.00.8–1.2
     60–1198384.31.00.8–1.2
    120+3633.01.10.8–1.5
    Cimetidine and other165166.31.00.8–1.2
    Time since cohort entry (mo)
      0–112018.21.10.7–1.7
     12–596270.20.90.7–1.1
     60–1195854.81.10.8–1.4
    120+2523.21.10.7–1.6
    Other only7570.01.10.8–1.3
    Time since cohort entry (mo)
      0–111816.61.10.6–1.7
     12–594342.21.00.7–1.4
     60–1191310.71.20.6–2.1
    120+10.61.70.0–9.4
  • Table 2

    Risk of prostate cancer among male users of H2 blockers in GHC relative to the general population of western Washington State, 1977–1996

    ObservedExpectedSIR95% CI
    All users403535.30.80.7–0.8
    Time since cohort entry (mo)
      0–114773.00.60.5–0.9
     12–59176230.10.80.7–0.9
     60–119130167.30.80.6–0.9
    120+5064.90.80.6–1.0
    By type(s) of H2 blocker used
    Cimetidine only191271.70.70.6–0.8
    Time since cohort entry (mo)
      0–111833.80.50.3–0.8
     12–5992109.40.80.7–1.0
     60–1195491.00.60.4–0.8
    120+2737.50.70.5–1.0
    Cimetidine and other151180.20.80.7–1.0
    Time since cohort entry (mo)
      0–111317.60.70.4–1.3
     12–595071.80.70.5–0.9
     60–1196564.01.00.8–1.3
    120+2326.70.90.5–1.3
    Other only6183.40.70.6–0.9
    Time since cohort entry (mo)
      0–111621.60.70.4–1.2
     12–593448.90.70.5–1.0
     60–1191112.30.90.4–1.6
    120+00.700.0–5.6a
    • a One-sided 97.5% CI.

  • Table 3

    Relation of cimetidine use to risk of breast cancer among female users of H2 blockers in GHC, 1984–1996

    Controls (N = 4740)Cases (N = 474)RR (95% CI)
    N%N%
    Ever used cimetidine
    No79316.78217.31.0
    Yes394783.339282.71.0 (0.7–1.2)
    No. of prescriptions
    Never used79316.78217.31.0
     176316.17515.80.9 (0.7–1.3)
     2–387418.49219.41.0 (0.7–1.4)
     4–10114624.211023.20.9 (0.7–1.3)
    11–2059012.45311.20.9 (0.6–1.2)
    21+57412.16213.11.0 (0.7–1.5)
    Time since first eligible prescription
    Never used79316.78217.31.0
    <2 yr95320.18818.60.9 (0.6–1.2)
    2 to <5 yr113423.910923.00.9 (0.7–1.2
    5 to <8 yr90619.19119.21.0 (0.7–1.3)
    8+ yr95420.110421.91.1 (0.8–1.4)
    Time since last prescription
    Never used79316.78217.31.0
    ≤1 yr180438.118238.41.0 (0.7–1.3)
    >1 yr to <2 yr49410.4479.90.9 (0.6–1.3)
    2 to <5 yr94119.88217.30.8 (0.6–1.2)
    5+ yr70814.98117.11.1 (0.8–1.5)
  • Table 4

    Relation of cimetidine use to risk of prostate cancer among male users of H2 blockers in GHC, 1984–1996

    Controls (N = 3920)Cases (N = 392)RR (95% CI)
    N%N%
    Ever used cimetidine
    No70818.16817.41.0
    Yes321281.932482.61.0 (0.8–1.4)
    No. of prescriptions
    Never used70818.16817.41.0
     155814.25514.01.0 (0.7–1.5)
     2–367317.25413.80.8 (0.6–1.2)
     4–1089922.99624.51.1 (0.8–1.5)
    11–2054213.84812.20.9 (0.6–1.4)
    21+54013.87118.11.4 (1.0–1.9)
    Time since first eligible prescription
    Never used70818.16817.41.0
    <2 yr68117.45413.80.8 (0.5–1.2)
    2 to <5 yr94824.210326.31.1 (0.8–1.6)
    5 to <8 yr79020.28120.71.1 (0.8–1.5)
    8+ yr79320.28621.91.1 (0.8–1.6)
    Time since last prescription
    Never used70818.16817.41.0
    ≤1 yr146137.315439.31.1 (0.8–1.5)
    >1 yr to <2 yr40710.4369.20.9 (0.6–1.4)
    2 to <5 yr74719.16917.61.0 (0.7–1.4)
    5+ yr59715.26516.61.1 (0.8–1.6)
PreviousNext
Back to top
March 2000
Volume 9, Issue 3
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cimetidine Use and Risk of Prostate and Breast Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cimetidine Use and Risk of Prostate and Breast Cancer
Mary Anne Rossing, Delia Scholes, Kara L. Cushing-Haugen and Lynda F. Voigt
Cancer Epidemiol Biomarkers Prev March 1 2000 (9) (3) 319-323;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cimetidine Use and Risk of Prostate and Breast Cancer
Mary Anne Rossing, Delia Scholes, Kara L. Cushing-Haugen and Lynda F. Voigt
Cancer Epidemiol Biomarkers Prev March 1 2000 (9) (3) 319-323;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Statin Use and Breast Cancer Risk
  • Tamoxifen and Longitudinal Mammographic Density Change
  • Cancer Predisposition Gene Mutations and Pancreatic Cancer
Show more Short Communications
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement